Martin Dietrich, MD, PhD

home / authors / martin-dietrich-md-phd

Articles

Updates in Treatment of HER2 Mutant NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Challenges Associated with Molecular Testing in NSCLC

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

Martin Dietrich, MD, PhD

April 12th 2022

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

Benjamin Levy, MD;Misako Nagasaka, MD, PhD;Timothy Craig Allen, MD, JD, FCAP;Martin Dietrich, MD, PhD;Hatim Husain, MD;Fernando C. Santini, MD

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Dr. Dietrich on Future Research Directions in Lung Cancer

Martin Dietrich, MD, PhD

September 3rd 2021

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer.

Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer

Martin Dietrich, MD, PhD

August 16th 2019

Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.

<1 2 3 4 5